Dulaglutide (Trulicity)_Dosage, benefits & legal status
Also known as Trulicity, Dulaglutide, LY2189265
A weekly GLP-1 shot for diabetes, with far less weight loss than the famous ones.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is Dulaglutide (Trulicity)?
Plain language first. The technical label stays, but it never stands alone.Overview
It lowers blood sugar and takes the edge off hunger. It is approved for type 2 diabetes only, and the weight loss is much smaller than what people expect from this drug family.
Dulaglutide is a GLP-1 drug, the same family as Ozempic. It copies a gut hormone that tells the pancreas to release insulin when blood sugar is high, and slows how fast the stomach empties.
What it's used for
A once-weekly injection for type 2 diabetes, taken to lower blood sugar. It also lowers the risk of heart problems.
How does Dulaglutide (Trulicity) work?
What it does in the body, and where.Dulaglutide copies GLP-1, a hormone your gut releases after eating. The trick is that it is stuck to a piece of an antibody, which stops your body clearing it for about a week.
- 01It binds the GLP-1 receptorThe same target as Ozempic and the same one tirzepatide hits alongside a second receptor.
- 02The pancreas releases insulin, but only when sugar is highThis is why it rarely causes low blood sugar on its own. The signal switches off when blood sugar drops.
- 03The stomach empties more slowlyFood sits longer, so you feel full sooner and blood sugar rises more gently after a meal.
- 04The antibody piece is why it lasts a weekPlain GLP-1 is gone in minutes. Attaching it to a large protein hides it from the enzymes that would break it down.
Acts on one receptor.
What else is it used for?
Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
- Lowering blood sugar in type 2 diabetesFDA-approved
- Lowering the risk of heart attack and stroke in people with type 2 diabetes, where a trial of 5.4 years found 12% fewer such eventsFDA-approved
- Weight loss, where the effect is real but much smaller than semaglutide or tirzepatideClinical use
How much, and do you cycle it?
The range, and whether you take breaks.0.75 up to 4.5 mg per week (start low, increase slowly), weekly. Taken continuously, with no planned breakFDA label
Blood sugar rises again when it stops, so it is treated as ongoing medication rather than a course. The label sets no end date.
How long does it stay in the body?
The half-life, and where the figure comes from.About 5 daysFDA label
Peak concentration is reached around 48 hours and steady state between the second and fourth weekly dose.
Source: Trulicity label section 12.3. Consistent with the population pharmacokinetic analysis, PMID 26507721.
You can compare this against the whole library to see where it sits.
How do I dose and price it?
Enter your vial and your dose. Pick a mix. We show the draw and the cost.The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.
Choose your mix
Measuring the water1 mL = one full 100-unit syringe.
Your draw
15 / 100 unitsHow do you store it?
Before mixing, and after.Dry powder in the freezer or fridge. Once mixed, fridge, and use within about a month.
Unmixed lyophilized Dulaglutide (Trulicity) keeps for a long time cold. Once you add water the clock starts: most reconstituted vials hold up for roughly 28 to 30 days at fridge temperature. Keep it out of light, and do not freeze it after mixing.
What are the side effects and cautions?
Known cautions and warnings for this compound.This comes as a ready-to-use pen, so there is nothing to mix and nothing to measure. The pen has no dose dial: each one holds a single fixed dose, and you pick the strength when you fill the prescription. Do not expect Ozempic-level weight loss. Head to head, semaglutide at 1 mg produced about 6.5 kg of weight loss against 3.0 kg for dulaglutide at 1.5 mg.
Who should avoid it
- A personal or family history of medullary thyroid cancer
- Multiple Endocrine Neoplasia syndrome type 2, an inherited hormone condition
- Known allergy to dulaglutide
- Pregnancy, without talking to your doctor
Stop and get help
- Severe stomach pain that does not go away, which can signal pancreatitis
- A lump or swelling in the neck, trouble swallowing, or a hoarse voice
- Signs of an allergic reaction such as face or throat swelling, hives, or trouble breathing
Common effects
- Nausea, especially in the first few weeks
- Diarrhoea or constipation
- Stomach pain
- Tiredness
- Injection-site reactions
- Weight loss of roughly 3 to 5 kg at the higher doses, which is modest for this drug family
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is Dulaglutide (Trulicity) approved?
And where the numbers on this page come from.Yes. Dulaglutide (Trulicity) is FDA approved and available on prescription in the United States.
- Approval statusFDA-approved
- RouteUnder the skin (subcutaneous)
- CheckedAugust 2026
What has happened recently
FDA-approved in September 2014 for type 2 diabetes, with the 3.0 mg and 4.5 mg strengths added in September 2020. It has never been approved for weight loss, and Lilly has not applied for that. Anyone prescribed this for weight loss is getting it off-label.
You can compare this against the whole library, or read how to check a seller.
- DoseFrom the drug label. The manufacturer tested this range and a regulator reviewed it.
- Vial sizeFrom what vendors typically list; not a recommendation.
- Sources
- Reviewed14 August 2026
What else is like Dulaglutide (Trulicity)?
Others in GLP-1 agonists, side by side.If you're weighing Dulaglutide (Trulicity), it's worth reading Exenatide (Byetta / Bydureon), Ecnoglutide, and Lixisenatide (Adlyxin) in the same class.
A weekly GLP-1 shot for diabetes, with far less weight loss than the famous ones.
- Dose
- 0.75 up to 4.5 mg per week (start low, increase slowly)
- How often
- Weekly
The first GLP-1 drug, found in lizard venom, now mostly retired.
- Dose
- 2 mg per week (the weekly form)
- How often
- Weekly
A GLP-1 approved in China and licensed to Pfizer, and not approved in the US.
- Dose
- 1.2 to 2.4 mg
- How often
- Once weekly
An approved GLP-1 that lost the race and left the US market.
- Dose
- Set by the label
- How often
- Once daily
10What these words mean
Show glossary +
What these words mean
- 503A and 503B
- The two kinds of compounding pharmacy in US law. A 503A pharmacy prepares medicine for one named patient. A 503B outsourcing facility makes larger batches under stricter manufacturing rules.
- Agonist
- Something that switches a receptor on. The opposite is an antagonist. It blocks the receptor instead.
- Amino acid
- The building blocks that link together in a chain to make a peptide or a protein. The order they sit in is what makes one peptide different from another.
- Amylin
- A hormone released alongside insulin that slows the stomach emptying and reduces appetite. Several weight loss compounds copy it.
- Analog
- A compound built to copy a natural one with small deliberate changes, usually so it lasts longer or holds onto its target more tightly.
- Animal study
- Research done in rats, mice or other animals. Most findings do not repeat in people, so an animal result is a reason to keep looking. It is not a reason to act.
- Antibody
- A large immune protein, far bigger than a peptide, engineered to lock onto one specific target. These are made by drug companies and are not sold as research powders.
- Bacteriostatic water
- Sterile water with a tiny amount of preservative, used to mix powdered peptides.
- Banned in drug-tested sport
- Prohibited by the World Anti-Doping Agency (WADA); using it can disqualify a competing athlete.
- Bioavailability
- How much of a dose actually reaches your bloodstream. Most peptides survive stomach acid badly, so most of them are injected instead of swallowed.
- Bioregulator
- Very short peptides from a Russian research tradition, usually two to four amino acids long, sold for supporting a specific organ. Human evidence is thin and most of it is published in Russian.
- Blend
- One vial holding more than one compound, mixed together by the seller. Working out a dose means working out each ingredient separately, because they are rarely present in equal amounts.
- Boxed warning
- The most serious warning the FDA puts on a drug label, printed inside a black border. It flags a risk considered severe enough to sit above everything else on the label.
- Bulks list
- The FDA's list of ingredients that compounding pharmacies are allowed to use. A substance can sit under review on it for years without anything being decided either way.
- Certificate of analysis (COA)
- A lab report on a batch of product. It only means something if it names the batch you actually received, comes from an independent lab, and can be checked with that lab.
- Clinical trial
- A study that gives a treatment to people under a written plan and measures what happens. It is the only kind of evidence that can show something works in humans.
- Compounding
- A licensed pharmacy preparing a medicine to order. Being allowed to compound something is not the same as the FDA approving it, and the two get mixed up constantly.
- Concentration
- How strong the mixed peptide is, in milligrams per milliliter (mg/mL). More water makes it weaker; less water makes it stronger.
- Cycle
- A stretch of time using a compound followed by a break. Most cycling patterns come from community practice. Very few have been tested.
- DAC
- Short for Drug Affinity Complex. An attachment added to a peptide so it grabs onto a blood protein and stays in the body for days instead of minutes.
- Dead space
- The small amount of liquid left sitting inside the needle and hub after you inject. On very small doses it can be a real share of what you meant to take.
- Dilute
- Adding more liquid to make a mix weaker. The amount of peptide in the vial does not change. It is just spread through more water, so each draw is bigger.
- Endpoint
- The result a trial said in advance that it would measure. A study can be reported as positive and still have missed the endpoint it set out to hit.
- FDA approved
- Reviewed by the FDA and cleared for a specific use, in a specific form, at a specific dose. Approval for one use is not approval for another, and approval in another country is not approval here.
- Fragment
- A short piece cut out of a larger natural protein. A fragment can behave very differently from the whole protein it came from, so evidence about one does not transfer to the other.
- Ghrelin
- The hunger hormone. Some growth hormone compounds work by copying it, so they can make you noticeably hungrier.
- GHRH
- A natural signal telling the pituitary gland to release growth hormone. Several compounds copy it.
- GHRP
- A second, separate signal that also triggers growth hormone release, through a different door than GHRH. This is why the two types are often used together.
- GLP-1
- A natural gut hormone that lowers appetite and blood sugar. Drugs that copy it, like semaglutide, are used for weight loss.
- Growth hormone secretagogue
- A compound that nudges your body to release more of its own growth hormone, rather than injecting the hormone itself.
- Half-life
- How long a compound stays active in your body. A longer half-life means you inject less often.
- HPLC
- A lab method that separates out everything in a sample so the amounts can be measured. It shows how much of the main ingredient is there. It does not confirm that the main ingredient is the right molecule.
- In vitro
- Done in a dish or a test tube, on cells outside a living body. It is the earliest kind of evidence there is.
- Injection site
- The spot on the body where you inject. Moving it around gives the skin and fat underneath time to recover between doses.
- Intramuscular (IM)
- An injection into a muscle, using a longer needle.
- Intravenous (IV)
- An injection into a vein. It needs training and equipment and is not something to do at home.
- Investigational
- Still being tested in clinical trials and not yet approved or legally sold for general use.
- Lyophilized
- Freeze-dried into a powder so it keeps longer. That is the white cake or dust in the bottom of an unmixed vial.
- Mass spectrometry
- A lab method that weighs molecules to confirm what they are. HPLC answers how much is in the sample. This answers what it is.
- mcg and mg
- Units of dose. 1 milligram (mg) equals 1,000 micrograms (mcg).
- Myostatin
- A natural brake on muscle growth. Several compounds are built to block it, though human results have been far smaller than the animal work suggested.
- Off-label
- A doctor prescribing an approved drug for something other than its approved use. This is legal and common, and it is different from a compound having no approval at all.
- Orphan drug designation
- A status given to treatments for rare conditions to make them worth developing. It is an incentive, not an approval, and a compound can hold it while being approved for nothing.
- PCAC
- The FDA advisory committee that reviews compounding ingredients. It recommends. It does not approve, and the FDA does not have to follow what it says.
- Peer review
- Other scientists checking a paper before a journal publishes it. It filters out some bad work. It does not make a finding true.
- Peptide vs small molecule
- A peptide is a short chain of amino acids. A few items here (like MK-677 or methylene blue) are small molecules, not true peptides, but people use them the same way.
- Placebo
- A dummy treatment given for comparison. Without one it is very hard to tell a real effect apart from expectation and time passing.
- Purity
- The share of a sample that is the intended compound, usually given as a percentage. A high purity number on the wrong molecule is still the wrong molecule.
- Randomized
- Deciding by chance who gets which treatment, so the two groups are comparable. Studies that skip this are much easier to read the wrong way.
- Receptor
- A docking point on a cell that a compound attaches to. If a cell has no matching receptor, the compound does nothing to it.
- Reconstitution
- Mixing a powdered peptide with liquid (bacteriostatic water) so it can be drawn into a syringe.
- Research only
- No approved dose or use in people. Sold for research and not reviewed by the FDA for safety or quality.
- Stack
- Using more than one compound at the same time. Almost no combinations have been tested together in people, so a stack is usually built on guesswork.
- Sterile water
- Water with nothing added to stop bacteria growing. It works for a single dose, but a vial mixed with it should not be kept and used again.
- Subcutaneous
- An injection just under the skin, into the fat layer, usually with a short, thin insulin needle.
- Titrate
- Starting at a low dose and increasing it slowly over time so your body adjusts and side effects stay mild.
- Trial phases
- The stages of human testing. Phase 1 checks safety in a small group, phase 2 looks for an effect, and phase 3 tests it against a comparison in a large group.
- Units (on the syringe)
- The marks on an insulin syringe. 100 units equals 1 mL. They measure how much liquid you draw, not the dose in milligrams.
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- Why Does My Peptide Injection Itch or Welt
Injection-site irritation, a histamine reaction, or a true allergy, and how to tell them apart.
- Semaglutide vs Tirzepatide vs Retatrutide
One receptor, two, or three. Mechanism, trial weight loss, side effects, and real cost.
Sources
- FDA, TRULICITY (dulaglutide) prescribing information(2020)Approved September 2014 for type 2 diabetes. Doses 0.75, 1.5, 3.0 and 4.5 mg once weekly. Boxed warning for thyroid C-cell tumours. No weight-loss indication.
Last reviewed 14 August 2026
Peptide Decoding is published by Decoded Sciences LLC. We take no payment from vendors for coverage, inclusion or ranking, and our affiliate relationships are disclosed in full.